These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 25701029)
1. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Huang Z; Gan J; Jia L; Guo G; Wang C; Zang Y; Ding Z; Chen J; Zhang J; Dong L Biomaterials; 2015 Apr; 48():26-36. PubMed ID: 25701029 [TBL] [Abstract][Full Text] [Related]
2. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease. Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374 [TBL] [Abstract][Full Text] [Related]
3. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action. Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725 [TBL] [Abstract][Full Text] [Related]
4. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369 [TBL] [Abstract][Full Text] [Related]
5. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. Nakase H; Okazaki K; Tabata Y; Chiba T J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874 [TBL] [Abstract][Full Text] [Related]
6. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. Nakase H; Okazaki K; Tabata Y; Uose S; Ohana M; Uchida K; Matsushima Y; Kawanami C; Oshima C; Ikada Y; Chiba T J Pharmacol Exp Ther; 2000 Jan; 292(1):15-21. PubMed ID: 10604927 [TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. Myers KJ; Murthy S; Flanigan A; Witchell DR; Butler M; Murray S; Siwkowski A; Goodfellow D; Madsen K; Baker B J Pharmacol Exp Ther; 2003 Jan; 304(1):411-24. PubMed ID: 12490618 [TBL] [Abstract][Full Text] [Related]
9. Carboxyamidotriazole ameliorates experimental colitis by inhibition of cytokine production, nuclear factor-κB activation, and colonic fibrosis. Guo L; Ye C; Hao X; Zheng R; Ju R; Wu D; Luo L; Wang C; Li J; Yu X; Zhu L; Zhang D J Pharmacol Exp Ther; 2012 Aug; 342(2):356-65. PubMed ID: 22553216 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Amini-Shirazi N; Hoseini A; Ranjbar A; Mohammadirad A; Khoshakhlagh P; Yasa N; Abdollahi M Toxicol Mech Methods; 2009 Feb; 19(2):183-9. PubMed ID: 19778264 [TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Naito Y; Katada K; Takagi T; Tsuboi H; Isozaki Y; Handa O; Kokura S; Yoshida N; Ichikawa H; Yoshikawa T Int J Mol Med; 2006 Jun; 17(6):997-1004. PubMed ID: 16685407 [TBL] [Abstract][Full Text] [Related]
12. TNF-alpha is crucial for the development of mast cell-dependent colitis in mice. Rijnierse A; Koster AS; Nijkamp FP; Kraneveld AD Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G969-76. PubMed ID: 16798721 [TBL] [Abstract][Full Text] [Related]
13. Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. Sakata A; Ochiai T; Shimeno H; Hikishima S; Yokomatsu T; Shibuya S; Toda A; Eyanagi R; Soeda S Immunology; 2007 Sep; 122(1):54-64. PubMed ID: 17451462 [TBL] [Abstract][Full Text] [Related]
14. Intestinal anti-inflammatory activity of luteolin: role of the aglycone in NF-κB inactivation in macrophages co-cultured with intestinal epithelial cells. Nishitani Y; Yamamoto K; Yoshida M; Azuma T; Kanazawa K; Hashimoto T; Mizuno M Biofactors; 2013; 39(5):522-33. PubMed ID: 23460110 [TBL] [Abstract][Full Text] [Related]
15. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Wang X; Yan J; Wang L; Pan D; Xu Y; Wang F; Sheng J; Li X; Yang M Theranostics; 2020; 10(23):10808-10822. PubMed ID: 32929381 [No Abstract] [Full Text] [Related]